OVERVIEW

We are a biopharmaceutical company focused on the discovery, acquisition, development and commercialization of novel drug candidates for central nervous system, or CNS, disorders. We currently have three product candidates in various stages of clinical development by us, namely, bicifadine, DOV 21,947 and DOV 102,677. We have entered into collaborations for two additional DOV product candidates, indiplon and DOV 216,303, and are seeking a partner for a third product candidate, DOV diltiazem. Bicifadine is our lead...